Skip Navigation


Rheumatology Advance Access originally published online on May 7, 2008
Rheumatology 2008 47(7):1097-1099; doi:10.1093/rheumatology/ken015a
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow full guidelines
Right arrow All Versions of this Article:
47/7/1097    most recent
ken015av2
ken015av1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Soriano, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Soriano, E. R.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context

E. R. Soriano1, C. Galarza-Maldonado2, M. H. Cardiel3, B. A. Pons-Estel4, L. Massardo5, C. V. Caballero-Uribe6, A. F. Achurra-Castillo7, L. A. Barile-Fabris8, J. Chávez-Corrales9, J. F. Díaz-Coto10, M. H. Esteva-Spinetti11, M. Guibert-Toledano12, F. Irazoque Palazuelos13, M. W. Keiserman14, A. V. Lomonte15, L. M. H. Mota16, C. Pineda Villaseñor17, G. S. Alarcón18 on behalf of GLADAR (Grupo Latino Americano de Estudio de Artritis Reumatoide)

1Sección Reumatología, Servicio de Clínica Médica, Hospital Italiano de Buenos Aires y Fundación Dr Pedro M. Catoggio para el Progreso de la Reumatología, Buenos Aires, Argentina, 2Unidad de Enfermedades Reumáticas y Autoinmunes, UNERA, Hospital Monte Sinai, Cuenca, Ecuador, 3Unidad de Investigación Dr Mario Alvizouri Muñoz, Hospital General Dr Miguel Silva, Morelia, México, 4Servicio de Reumatología, Hospital Provincial de Rosario, Rosario, Argentina, 5Departamento de Inmunología Clínica y Reumatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile, 6Unidad de Reumatología, Hospital Universidad del Norte, Barranquilla, Colombia, 7Complejo Hospitalario Metropolitano Dr Arnulfo Arias Madrid, Caja de Seguro Social de Panamá and Sociedad Panameña de Reumatología, Ciudad de Panamá, Panamá, 8Departamento de Reumatología, Hospital de Especialidades Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, IMSS, México DF, México, 9Servicio de Reumatología, Hospital Nacional Edgardo Rebagliati Martins, Red Asistencial Rebagliati (RAR), ESSALUD, Lima, Perú, 10Hospital México, Caja Costarricense del Seguro Social, San José, Costa Rica, 11Unidad de Reumatología, Hospital Central de San Cristóbal, Tachira, Venezuela, 12Servicio Nacional de Reumatología, Hospital Clínico Quirúrgico Diez de Octubre, Ciudad Habana, Cuba, 13Centro Médico Nacional 20 de Noviembre ISSSTE, México DF, México, 14Rheumatology Unit, São Lucas Hospital, PUCRS, Porto Alegre, 15Serviço de Reumatología, Hospital Heliópolis, São Paulo, 16Hospital Universitário de Brasília, Universidade de Brasília, Brasília, Brazil, 17Instituto Nacional de Rehabilitación, México DF, México and 18Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, NY, USA

Correspondence to: C. Galarza-Maldonado, Hospital Monte Sinai, Unidad de Enfermedades Reumáticas y Autoinmunes, Miguel Cordero 6111 y Solano, Cuenca, Ecuador. E-mail: claudiogalarza@hotmail.com

KEY WORDS: Rheumatoid arthritis, Treatment guidelines, Biologic therapy, Anti-CD20 antibody, Rituximab, Latin America

The first 10% of the full text of this article appears below.


   Executive summary
 
Scope and purpose of the guidelines
GLADAR (Grupo Latino Americano de Estudio de Artritis Reumatoide) is a large group of Latin American (LA) rheumatologists experienced in the diagnosis and treatment of RA. In 2006, PANLAR and GLADAR published the first LA position paper on the pharmacological treatment of RA [1]. Since then, new therapies have emerged to help achieve the ultimate goal to preserve the patient's ability to function independently with an optimal quality of life.

The current guidelines provide evidence-based advice on the use of rituximab for physicians and rheumatologists treating RA in LA. A recent consensus publication has emanated from a group of European . . . [Full Text of this Article]


   Guidelines for the use of rituximab in RA in LA
 
Indications for rituximab
Who should administer rituximab?
How should patients be screened before initiating rituximab?
How patients should be treated?
How should patients be evaluated?
Contraindications
Switching anti-TNF or giving rituximab

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?